|
Post by loparn on Nov 1, 2017 19:14:29 GMT
ExpreS2ion Biotech Holding expres2ionbio.com/ finance.yahoo.com/quote/EXPRS2.ST?p=EXPRS2.STI have become increasingly convinced that ExpreS2ion is a real yet relatively "undiscovered jewel" I "stumbled on" considering the company's market value November 1, around SEK 122 million after full dilution (around USD 15 million) seen in relation to, among other things, the amazing potential of the joint venture company AdaptVac, which is scientifically well based in research at the University of Copenhagen. ExpreS2ion has a risk spreading advantage in a large number of existing and upcoming projects in therapeutic and common prophylactic vaccines, as well as an established growing business with a technology platform for the production of complex proteins for vaccines. My new analysis can be found here www.infoom.se/mysite/index.php?sida=80827&user=9801
|
|
|
Post by loparn on Nov 8, 2017 20:06:43 GMT
|
|
|
Post by loparn on Nov 16, 2017 20:31:52 GMT
|
|
|
Post by loparn on Nov 28, 2017 18:16:58 GMT
News release Nov 28 : "Proof of Concept in Animals for AdaptVac’s breast cancer vaccine candidate published in scientific journal Hørsholm, Denmark, 28 November 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”)’s 50% owned joint venture, AdaptVac’s, scientific paper presenting proof of concept in animals (POCA) for its novel breast cancer vaccine candidate, AV001, will be published in the peer reviewed scientific journal ‘OncoImmunology’. The results demonstrate that AV001 is effective for both prevention and therapy of breast cancer in an advanced mouse model. “I am very pleased that the previously announced data demonstrating proof concept in animals for AdaptVac’s breast cancer vaccine candidate is now published in a renowned peer reviewed journal. These convincing data constitute an important step towards reaching a license or collaboration agreement with a strong partner for the project”, says Dr. Steen Klysner, CEO of ExpreS2ion Biotechnologies. AdaptVac’s scientific paper "Virus-like particle display of HER2 induces potent anti-cancer responses" will be published online today. The data for the proof of concept in animals for AV001 is based upon targeting so-called HER2-positive breast cancer tumours. The tumours were generated in an advanced HER2 transgenic mouse model. HER2 (human epidermal growth factor receptor 2) is a specific gene that plays a significant role in the development of breast cancer. In the POCA study the article is based upon, the vaccine is demonstrated to be effective for both prevention and therapy of HER2-positive breast cancer tumours. The effect compares very well with the leading monoclonal antibody therapy on the market today. In addition, the results indicate a potential for AV001 as a rescue therapy for non-responders or patients for whom the treatment with monoclonal antibodies fails due induce immune response. AdaptVac’s press release, as well as the full article, when available, can be found at AdaptVac’s website: www.adaptvac.com/news Strong market potential Breast cancer affect more than 1.3 million worldwide annually, resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) generates annual global sales of US$ 7 billion. The target product profile of AdaptVac's lead breast cancer project is highly competitive to this in terms of cost and efficacy, thus aiming at a significant market share. About AdaptVac ApS AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, combining ExpreS2ion’s platform with novel proprietary and ground-breaking Virus-Like Particle (VLP) technology, developed at the University of Copenhagen. The company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. " expres2ionbio.com/investor/international-press-releases/details/?id=18CAA95C723FD2DA
|
|
|
Post by loparn on Nov 29, 2017 17:35:32 GMT
|
|
|
Post by loparn on Dec 4, 2017 9:10:58 GMT
|
|
|
Post by loparn on Dec 5, 2017 21:29:42 GMT
|
|
|
Post by loparn on Dec 11, 2017 12:04:15 GMT
|
|
|
Post by loparn on Dec 28, 2017 14:52:22 GMT
|
|
|
Post by loparn on Jan 5, 2018 22:12:49 GMT
The scientific article regarding the HER2-project in breast cancer is now open : www.tandfonline.com/doi/full/10.1080/2162402X.2017.1408749?scroll=top&needAccess=true"Monomeric proteins are generally weak immunogens and simple subunit vaccines based on a soluble protein antigen in an adjuvant formulation have almost exclusively failed in clinical trials due to insufficient efficacy. In the context of anti-cancer vaccines multiple mechanisms moreover prevent induction of immune responses against self. Central T-cell tolerance prevent the egress of auto-reactive T cells from the thymus and the tumor environment imposes additional immune tolerogenic mechanisms to prevent induction of CD4+ T-helper cells." "Contrary to monomeric proteins, surface of virus-like particles (VLPs) are highly immunogenic due to sharing key characteristics with live viruses." The VLP-technology of ExpreS2ion/AdaptVac thus has a huge potential to induce antibodies against selected interesting antigens such as HER2, PD-L1, CTLA-4, IL-5 etc.
|
|
|
Post by loparn on Jan 19, 2018 19:26:31 GMT
|
|
|
Post by loparn on Feb 23, 2018 6:29:20 GMT
The CSO of ExpreS2ion Biotech Holding and CEO of its joint-venture AdaptVac Willem "Wian" A. de Jongh, PhD speaks at the ISBiotech conference in US March 5-7 about the VLP-technology (Virus-like particles) and ExpreSion/AdpatVac's promising HER2-project in breast cancer. "HER2 Cancer Vaccine Optimization by Combining Drosophila S2 Insect Cell Manufacturing with a Novel VLP-Display Technology" www.isbiotech.org/baculovirusThe goal is to reach a partner deal this year regarding the HER2-project specifically or the VLP-platform in general. That is most likely the biggest trigger in 2018 for the ExpreS2ion Biotech Holding stock. The market capital of ExpreS2ion is around USD 17.5 million and my belief is that a good deal could be worth a lot more, maybe 2-3 times current market capital or more. The VLP technology could be a possible threat to and compete with producers of extremely expensive monoclonal antibodies (for example used in cancer against HER2, PD-L1, CTLA-4 etc and other diseases such as asthma IL-5) since the vaccines produced by the platform, via the body's own B-cells, can generate antibodies against, in principle, any antigen chosen for the VLP-vaccine (proved in mice for many different antigens www.ncbi.nlm.nih.gov/pmc/articles/PMC4847360/ www.tandfonline.com/doi/full/10.1080/2162402X.2017.1408749 ). And combined with ExpreS2ion's own world leading complex protein production platform ExpreS2, the company should be able to produce the actual vaccines in house. A rather unique feature of the VLP-technology is that it can direct the immune system against chosen self-proteins (such as HER2), so instead of administrating expensive monoclonal antibodies, the VLP-vaccine cause the human body's B-cells to produce natural antibodies at a low cost. After the ongoing and soon ending rights issue, which has temporarily put a pressure down on the stock value, ExpreS2ion should have enough capital to reach their goals. expres2ionbio.com/
|
|
|
Post by loparn on Mar 1, 2018 21:27:32 GMT
"Upcoming Webinar Developing a HER2-VLP vaccine for treatment of HER2-positive cancer Date: Wednesday, March 14, 2018 Time: 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT / 9:00 AM PDT Speakers Willem (“Wian”) Adriaan de Jongh, PhD CSO, ExpreS2ion Biotechnologies Affiliated Associate Prof. Technical University of Denmark Adam Frederik Sander Pedersen, PhD Associate Prof. Copenhagen University CSO, AdaptVac Moderator Donna Weerd-Wilson Executive Publisher Vaccine Register now. Please join us on March 14th for a free webinar on “Developing a HER2-VLP vaccine for treatment of HER2-positive cancer; optimizing the potential by combining Drosophila S2 insect cells manufacturing with a novel VLP-display technology.” In this webinar, you will learn about the combination of a unique Drosophila S2 insect cell based protein expression system and a novel virus-like particle (VLP) technology to develop improved profylactic and therapeutical treatments for oncology and infectious disorders. Visit the webinar Registration Page for details and to register for free. We hope you will attend this event Sponsors Vaccine ExpreS2ion Biotechnologies " www.journals.elsevier.com/vaccine/webinars/upcoming-webinar-developing-a-her2-vlp-vaccine-for-treatment
|
|
|
Post by loparn on Apr 20, 2018 9:15:37 GMT
"ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product" expres2ionbio.com/investor/international-press-releases/details/?id=36E16359BC1D3C07Note also that there is a synergy between the ExpreS2 and VLP platforms since it is also stated that they have also produced 35 virus-like particles. Thus it is likely they can produce the VLPs a licensee to ExpreS2ion's joint venture AdaptVac's VLP platform would need for therapeutic and/or prophylactic VLP-based vaccines. Both platforms combined can therefore be attractive for a licensee who wants to develop relatively cheap VLP-based vaccines, for example, to potentially outperform several monoclonal antibodies that sell for USD billion against for example cancer or in combination therapy with such monoclonal antibodies. "Virus-like antigen display for cancer vaccine development, what is the potential?" "The data thus indicates that the HER2-VLP vaccine has potential to overcome immune tolerance and to elicit broad, humoral and cellular immunological responses, fulfilling the theoretical goals for a next generation anti-cancer vaccine design." www.tandfonline.com/doi/pdf/10.1080/14760584.2018.1455505?needAccess=true
|
|
|
Post by loparn on Jun 15, 2018 6:59:59 GMT
ExpreS2ion will present its malaria and breast cancer vaccine research at two scientific events in June ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will hold presentations at an annual meeting hosted by the World Biopharm Forum in Oxford, UK, June 20-22 and at the Vaccine Technology VII Meeting in Mont Tremblant, Quebec, Canada, June 17-22. “These events will let us present ExpreS2ion’s globally acknowledged platform for developing and producing vaccines that can be used for both infectious diseases and novel cancer treatments. As we are at the forefront in developing promising vaccines for large patient groups, there is a lot of interest in our work from the scientific community as well as from pharmaceutical companies in different parts of the world,” says ExpreS2ion’s CEO Dr. Steen Klysner. expres2ionbio.com/investor/international-press-releases/details?id=7B56F941AA4F4B49
|
|
|
Post by loparn on Sept 6, 2018 6:55:06 GMT
|
|
|
Post by loparn on Sept 10, 2018 6:46:26 GMT
|
|
|
Post by loparn on Oct 3, 2018 12:14:15 GMT
|
|
|
Post by loparn on Oct 24, 2018 7:14:40 GMT
Newsrelease : "ExpreS2ion announces upcoming presentation of Phase I/IIa malaria vaccine trial results by Jenner Institute Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, Jenner Institute of the University of Oxford, will present the results from the Phase I/IIa clinical studies of its RH5.1 blood stage malaria vaccine at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on the 31st of October in New Orleans." expres2ionbio.com/investor/international-press-releases/details/?id=F27FE75BFAF9627E
|
|
|
Post by loparn on Oct 31, 2018 17:31:33 GMT
"ExpreS2ion announces positive Phase I/IIa malaria vaccine trial results by The Jenner Institute, University of Oxford Horsholm, Denmark, October 31 2018 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown to be safe and it is the first vaccine to demonstrate a reduction in the parasite multiplication rate following a blood-stage controlled human malaria infection. In the results it is concluded, that RH5.1 is safe, immunogenic, and has a moderate, but significant, impact on parasite multiplication rate following primary and secondary controlled human malaria infection (CHMI) with blood-stage P. falciparum. Furthermore, the delayed fractional dosing arm of the study shows highly promising improved immunogenicity leading to a stronger, longer-lasting, and improved avidity antibody response. The AS01B adjuvant used in this study was supplied by the global pharmaceutical company GlaxoSmithKline. “The promising results from this clinical study are a great achievement from the University of Oxford group and an important step towards creating a malaria vaccine for a broader large-scale use. We are excited to be a collaboration partner and delighted that our ExpreS2 platform is used for the development and production of their cutting-edge RH5.1 malaria vaccine,” says ExpreS2ion’s CEO Dr. Steen Klysner. “The encouraging results from this RH5.1 Phase I/IIa malaria study are in line with our preclinical findings and form a solid foundation on which to build the next steps in our blood-stage malaria vaccine clinical programme. We are grateful to ExpreS2ion for providing the enabling ExpreS2 development and production platform, and their contribution to the project as a whole,” says Professor Dr. Simon Draper, Leader of The Jenner Institute’s Blood-Stage Malaria Vaccine Group. In addition to the RH5.1 clinical program, ExpreS2ion’s patented ExpreS2 platform is currently being used in several other malaria vaccine projects, of which one is also a collaboration with University of Oxford. ExpreS2 is also utilised in a number of projects elsewhere for the development of vaccines for major health threats such as Ebola and breast cancer. The breast cancer project is developed by the Company’s joint venture AdaptVac." expres2ionbio.com/investor/international-press-releases/details/?id=4B38BFD01F05EFC0
|
|